Nootropic agent
CA 2301782 A1 · Owner: Watabe, Shigeo · Inventors: Watabe, Shigeo; Nishizaki, Tomoyuki; Yoshii, Mitsunobu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A drug which improves cerebral neurotransmission based on interaction of long-term activation of a protein kinase C pathway and long-term activation of presynaptic nicotinic acetylcholine (nACh) receptors, and on an accompanying increase in the amount of released glutamate which, activates cerebral neurotransmission over a prolonged period. The substances of the present invention serve as excellent nootropic. They are particularly useful for the therapy of dementia caused by hydrocephalus, or by subdural hemorrhage.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 14, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 14, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 14, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.